US FDA approves Actavis generic copy of GSK's Valtrex and Hi-Tech's lidocaine; Cephalon wins Fentora patent case
Iceland-based generic drugmaker Actavis Group says it has received approval from the US Food and Drug Administration to market valaciclovir hydrochloride tablets, used to treat herpes virus infections.
Valaciclovir 500mg and 1gram, the generic equivalent of UK drug giant GlaxoSmithKline’s Valtrex, had US sales of approximately $1.5 billion for the 12 months ending December 31, 2010, according to IMS Health.
Actavis launched valaciclovir in France and a number of other European Economic Area countries. Valaciclovir was one of the top selling drugs coming off patent in France in 2009.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze